Q4 2025 Tactile Systems Technology Inc Earnings Call Transcript

Feb 17, 2026 / 10:00 PM GMT

Release Date Price: $28.05 (+6.05%)

Transcript 10-K8-K

Key Points

Positve

Tactile Systems Technology Inc (TCMD) reported a 12% year-over-year increase in total revenue for 2025, reaching $329.5 million.
The company expanded its full-year gross margins by 190 basis points to 75.9% and increased adjusted EBITDA by 21% to $44.8 million.
Tactile Systems Technology Inc (TCMD) successfully repaid its full outstanding principal balance of $26.3 million and repurchased $26.5 million of its stock.
The company ended 2025 with $83.4 million in cash and cash equivalents and generated nearly $43 million in operating cash flow.
The acquisition of Lymphotec is expected to enhance Tactile Systems Technology Inc (TCMD)'s capabilities in assessing and monitoring fluid in patients with chronic swelling, potentially accelerating therapy access for undiagnosed patients.

Negative

The introduction of a new Medicare prior authorization requirement for pneumatic compression devices may temporarily impact the lymphedema market.
Operating expenses increased by 20% to $62.2 million, driven by strategic investments in sales and marketing, research and development, and general administrative expenses.
Income tax expense rose by 169% year-over-year to $8.8 million.
Interest income decreased by 28% to $0.7 million due to a decreased cash position.
The new Medicare prior authorization requirement could slow down the growth of the lymphedema market in the short term as the industry adjusts to the change.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TCMD.OQ - Tactile Systems Technology Inc
Q4 2025 Tactile Systems Technology Inc Earnings Call
Feb 17, 2026 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Please stand by. Welcome, ladies and gentlemen to the 4th quarter in full year 2025 earnings conference call for Tactile Medical.

At this time, all participants have been placed in listen-only mode. At the end of the company's prepared remarks, we will conduct a question-and-answer session.

Please note that this conference call is being recorded and will be available on the company's website for replay shortly.

I would now like to turn the call over to SAM Benzinger, investor relations at Gil Martin Group, for a few introductory comments. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.